Key Drivers
- Strong liquidity
- Negative FCF
- Improving gross margin
AIAI Summary
OPKO has shifted from a diagnostics cash‑flow story to a partner‑funded, high‑binary R&D platform where near‑term valuation now hinges on timely milestone payments (Regeneron/ModeX/Merck/Pfizer) rather than steady diagnostic growth, backed by a meaningful cash runway but facing sustained negative FCF and concentrated revenue risk. The critical action: monitor upcoming partner milestone timelines and cash‑receipt cadence—failure to realize those payments or durable diagnostic margin recovery will likely force dilution or downside, while confirmed material milestones would unlock asymmetric upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Negative FCF
- •Improving gross margin
OPK shows strong near-term liquidity and rising gross margins but is severely constrained by persistent operating losses, deep negative free cash flow, and a heavy intangible asset base.
Price Behavior
Key Price Behavior Insights:
- •Below SMA
- •Near support
- •Weakening momentum
Over the last month OPK is in a mild short-term downtrend—trading below the ~$1.18 SMA at $1.12 with RSI ~35 approaching oversold, sitting on support $1.12–$1.15 and facing resistance $1.19–$1.21, so watch for a volume-confirmed bounce or a risky breakdown below $1.12.
Modest price range ~$1.12–$1.24 over the period limits breakout potential
Sentiment & News
Key News Insights:
- •Q4 beat
- •Regeneron deal
- •Margin pressure
OPKO beat near-term expectations with a smaller-than-expected Q4 loss and revenue beat, announced a multispecific antibody collaboration with Regeneron, but faces declining sales, margin pressure and concentrated product risk.
The Regeneron collaboration and earnings beat may stabilize sentiment short-term, but persistent revenue decline and concentration risk constrain upside until diversification or sustained sales recovery occurs
Similar Companies in Healthcare
Other companies in the same sector with AI ratings